Neil Dunavin, MD
Hematology · San Francisco, CANPI 1578798369
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 60.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology clinicians in CA, where the typical reported total is $4,615.
Across 2 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25
- Pharmacyclics LLC, An Abbvie Company$17
Across 16 payments — averaging $18,769 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$222K
- Otsuka Pharmaceutical Co., Ltd.$42K
- Novartis$36K
What the payments were for
- Food & beverage$42100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
How this compares
$42 in reported general payments places this provider in the 5th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 85 | $1,307,117 |
| PromactaEltrombopag Olamine | 30 | $867,513 |
| IdhifaEnasidenib Mesylate | 25 | $798,340 |
| RezurockBelumosudil Mesylate | 21 | $730,694 |
| AyvakitAvapritinib | 12 | $416,005 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $314,811 |
| CresembaIsavuconazonium Sulfate | 17 | $101,114 |
| PrevymisLetermovir | 14 | $100,419 |
| Posaconazole | 25 | $16,164 |
| Atovaquone | 30 | $13,933 |
| Entecavir | 21 | $10,746 |
| Ursodiol | 26 | $4,671 |
| Acyclovir | 105 | $2,277 |
| Granisetron Hcl | 12 | $2,275 |
| Prednisone | 73 | $566 |
Paid to pharmacies, not to this prescriber.
Other hematology in San Francisco
- Hope RugoSan Francisco$537K
- Andrew LeavittSan Francisco$145K
- Everett MeyerStanford$2.1M
- Doris QuonLos Angeles$1.5M
- Amrita KrishnanDuarte$671K
- Ilene WeitzLos Angeles$631K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Caroline PiatekLos Angeles$391K
- Deepu MadduriStanford$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.